The CEO of Outlook Therapeutics discusses the FDA approval of wet AMD drug Lytenava; Roche receives a major boost in its efforts to commercialize wet AMD treatment Susvimo in Europe; and Glaukos reaches a milestone in its pivotal clinical study of the Preserflo MicroShunt. Learn more about your ad choices. Visit megaphone.fm/adchoices
Podzilla Summary coming soon
Sign up to get notified when the full AI-powered summary is ready.
Free forever for up to 3 podcasts. No credit card required.
Listen to This Episode
More from Eyewire News: The Podcast
PRIMA Retinal Implant Launched in EU
Tarsus Buys Investigational Ocular Antiseptic
Viridian Executive Discusses FDA Approval of New TED Therapy
Ocular Updates Plans for Axpaxli NDA for Wet AMD
Get summaries like this every morning.
Free AI-powered recaps of Eyewire News: The Podcast and your other favorite podcasts, delivered to your inbox.
Free forever for up to 3 podcasts. No credit card required.